SuperworthAdaptive Biotechnologies profit margin ADPT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- −20.7%
- Operating margin, 12 months
- −12.2%
- Net margin on a year earlier
- +38.3 pts
- Peer median
- 22.9%
Over the twelve months to Jun 30, 2026, Adaptive Biotechnologies kept −20.7% of its revenue as net profit, with an operating margin of −12.2% and a gross margin of 75.6%.
The median for 10 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −21.5% | −20.6% | 74.2% |
| FY2024 | −89.1% | −90.8% | 59.7% |
| FY2023 | n/a | n/a | 55.6% |
| FY2022 | n/a | n/a | 68.7% |
| FY2021 | n/a | n/a | 68.1% |
| FY2020 | n/a | n/a | 77.1% |
| FY2019 | −80.6% | −92.1% | 73.8% |
| FY2018 | −83.4% | −89.4% | 64.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −20.7% | +38.3 pts | −12.2% | |
| Q1 FY26 | −16.8% | +58.0 pts | −15.8% | |
| Q4 FY25 | −21.5% | +67.6 pts | −20.6% | |
| Q3 FY25 | −31.5% | n/a | −30.9% | |
| Q2 FY25 | −59.1% | n/a | −59.0% | |
| Q1 FY25 | −74.8% | n/a | −75.7% | |
| Q4 FY24 | −89.1% | n/a | −90.8% | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Adaptive Biotechnologies' size, closest first, today.
| Company | Profit margin |
|---|---|
| ADPTAdaptive Biotechnologies | −20.7% |
| ADMAAdma Biologics | 33.0% |
| VCELVericel | 7.9% |
| KRYSKrystal Biotech | 54.8% |
| RGENRepligen | 5.3% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| MGTXMeiraGTx | 19.9% |
| INCYIncyte | 27.7% |
| Peer median | 22.9% |
Where Adaptive Biotechnologies ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Adaptive Biotechnologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.